Loading stock data…
SNN
$30.90-0.26 (-0.83%)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Smith & Nephew plc in the Healthcare sector is trading at $30.90. The stock is currently 20% below its 52-week high of $38.79, remaining 8.5% below its 200-day moving average. Technical signals show oversold RSI of 26 and bearish MACD signal, explaining why SNN maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 26) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$30.90
Potential Downside
11.1%
Whystock Fair Value$27.48
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Hold
Mean target$36.06+16.7%
Range$32.00 – $39.00
Fundamentals
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Me...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.97B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
22.90
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Strong income play. Yield provides a meaningful total return floor.
239.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
11.82%
Volume
Today's trading volume
1.39M
Recent News
Canaccord Cuts PT on Smith & Nephew (SNN) Ahead of Fiscal Q1 Results
Smith & Nephew plc (NYSE:SNN) is one of the best medical device stocks to invest in right now. Canaccord cut the price target on Smith & Nephew plc (NYSE:SNN) to $32 from $35 on April 24 and reaffirmed a Hold rating on the shares. The firm updated its model ahead of the fiscal Q1 results. In […]
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
European equities traded in the US as American depositary receipts were trending lower late Monday m
Here's Why We Think Smith & Nephew (LON:SN.) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
SNN's CARTIHEAL Cartilage Implant Beats Standard Care in 5-Year Study
Smith+Nephew's CARTIHEAL implant shows superior 5-year outcomes vs. standard care, with a new CPT code set to boost adoption and expand cartilage repair reach.
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
European equities traded in the US as American depositary receipts were tracking higher late Friday